There was an interesting conversation on the "other" board today. One of the posters suggested BiOasis start proceeding into primate trials.
What for??!
I don't think we need to go there - why do all the leg work??
Here is a great comment courtesy of JDStox (one of the more knowledgeable posters on BTI)
No monkey trials!
Don't need them for Transcendpep, not directly. It would be a waste of time and money.
Because there will likely be such a wide array of drugs conjugated with Transcendpep, it stands to reason that some of them would have to be tested in primates but that has little to do with Transcendpep. Transcendpep's job is to get the drugs across the BBB. It's the drug's job to be safe and efficacious and those qualities may first need primate trials.
Yesterday's news seems to confirm the case that biOasis could have a very profitable side business of providing conjugates to researchers in a host of applications. Some of those applications will represent bleeding edge research and we can expect to see all sorts of research methods and protocols to be used.
But few, if any, Transcendpep conjugates are expected to require extraordinary trials just by virtue of having Transcendpep as a part of the conjugate. It's the drug that would mostly drive and inform the research and testing decisions.
I've said all along that the investing public does not understand, or more accurately, does not appreciate the significance and potential value of any kind of a BBB vector, let alone Transcendpep, which is living up to our hopes of being a near universal vector.
Just wait. They're going to "get it."
jdstox
